Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477281 | 0.98 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL29016445 | 0.80 | MMP1 (0.32) | ALDH1A1MMP1MMP2MMP3MMP9 | |
| SCHEMBL4058036 | 0.79 | SIGMAR1 (0.34) | — | |
| SCHEMBL1785410 | 0.76 | MAPT (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8164117 | 0.74 | — | — | |
| SCHEMBL6632132 | 0.72 | ALDH1A1 (0.36) | ALDH1A1MMP1MMP2MMP3MMP9 | |
| SCHEMBL3690670 | 0.71 | CYP2D6 (0.33) | SMN1; SMN2CYP2C19 | |
| SCHEMBL909008 | 0.70 | MITF (0.37) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6768696 | 0.69 | MEN1 (0.34) | ALDH1A1SMN1; SMN2MEN1CYP1A2CYP3A4 | |
| SCHEMBL23850269 | 0.69 | ALDH1A1 (0.38) | ALDH1A1MMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| EP-0926164-B1 | Substituted amino silane compounds and catalyst for the polymerization of alpha-olefins containing them | BASELL NORTH AMERICA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6130180-A | Catalyst for the polymerization of alpha-olefins containing substituted amino silane compounds | MONTELL NORTH AMERICA INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0926164-A2 | Substituted amino silane compounds and catalyst for the polymerization of alpha-olefins containing them | MONTELL NORTH AMERICA INC. (US) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | ALDH1A1 318/4885MMP1 3746/4885MMP2 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.